Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STSP 0902

Next Previous
X
Search
Drug Profile

STSP 0902

Alternative Names: STSP-0902

Latest Information Update: 01 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Staidson Beijing BioPharmaceuticals
  • Class Eye disorder therapies; Infertility therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthenozoospermia; Neurotrophic keratopathy; Oligospermia

Most Recent Events

  • 19 Sep 2024 Staidson (Beijing) Biopharmaceuticals plans a phase I pharmacokinetic trial in Healthy volunteers in China (Opthalmic, Liquid) (NCT06597422)
  • 10 Sep 2024 Preclinical trials in Neurotrophic keratopathy in China (Ophthalmic) before September 2024 (Staidson Beijing Biopharmaceuticals pipeline, September 2024)
  • 26 Aug 2024 Preclinical trials in Asthenozoospermia in China (SC) before August 2024 (Staidson Beijing Biopharmaceuticals pipeline, August 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top